Anti-angiogenic therapies for children with cancer

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• Tumor angiogenesis, the formation of new blood vessels in tumors, is crucial for cancer growth and metastasis.
• Anti-angiogenic treatments are established in adult cancer therapy, targeting key pathways like VEGFR and PDGFR.
• The role and therapeutic potential of anti-angiogenesis in pediatric solid tumors are still under early investigation.

Purpose of the Study:

• To review the critical role of tumor angiogenesis in pediatric solid tumors.
• To summarize pre-clinical and clinical findings on anti-angiogenic compounds for treating childhood cancers.
• To highlight the current status and future directions of anti-angiogenic strategies in pediatric oncology.

Main Methods:

• Literature review of pre-clinical studies and clinical trials.
• Analysis of anti-angiogenic agents targeting tumor vasculature.
• Focus on agents like bevacizumab, receptor tyrosine kinase inhibitors, cilengitide, and metronomic chemotherapy.

Main Results:

• Tumor angiogenesis significantly contributes to the progression of pediatric solid tumors.
• Several anti-angiogenic agents demonstrate pre-clinical efficacy and are entering clinical evaluation for pediatric cancers.
• Established adult anti-angiogenic strategies are being adapted for childhood cancer treatment.

Conclusions:

• Anti-angiogenic therapies represent a promising avenue for treating pediatric solid tumors.
• Further clinical investigation is essential to establish the safety and efficacy of these treatments in children.
• Targeting tumor angiogenesis holds potential for improving outcomes in pediatric cancer patients.